Achieve Life Sciences Inc (ACHV)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$6.38-8.67%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · ACHV
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -55.0% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name operates in a high-miss-rate industry and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
ACHV — CFO transition
Dated 2026-10-01
CFO — Benjamin Halladay: The filing announces the appointment of a new external CFO, which is a significant management change but not a departure of a sitting executive.
Why it matters: The company is funding trials and launch work while reporting losses. Cash use can show how much time the financing gives those plans.
Watch forThe next report shows cash sufficient for planned Q4 filing work, with spending in line with the stated trial and launch plans.
Also watch forThe next report shows a sharp cash drop, higher losses without clear progress, or new financing needs.
Why it matters: The August filing permits sales of up to $150 million in shares. Actual sales can add shares and raise cash for company needs.
Worry ifA filing reports ATM share sales near the $150 million limit, or a large rise in shares outstanding tied to the program.
Less concerning ifThe company reports no ATM sales, or only small sales, in its next filings.
Why it matters: The company said it expected a Complete Response Letter by June 20, 2026. The letter and its stated reasons set the next regulatory steps.
Watch forThe FDA letter notes no new clinical issue. The company confirms its Q4 2026 resubmission plan remains on track.
Also watch forThe FDA letter cites a clinical or safety issue, or the company says the Q4 filing plan must move.
Why it matters: The company plans to resubmit its smoking-cessation application in Q4. A timely filing would keep its stated launch plan on track.
Supportive ifIn Q4 2026, the FDA confirms it received a complete NDA resubmission. It names Adare as the main maker for sale.
Worry ifThe company does not resubmit by December 31, 2026, or the FDA says the filing is not complete.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$200 on $10,000 · ±2.0% | How much price usually moves either way. |
| Bad day | $671 loss on $10,000 · 6.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,455 loss on $10,000 · 54.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The company has stated a first-half 2027 U.S. launch goal. New dates and supply details can show whether that plan still holds.
Watch forThe November 5 update keeps the first-half 2027 launch goal and gives dated steps for filing and launch supply.
Also watch forThe update moves the first-half 2027 launch goal or reports that supply or filing work is behind schedule.